Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3YJZ7
|
|||
| Drug Name |
Zilovertamab vedotin
|
|||
| Synonyms |
MK-2140
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2/3 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotrophic tyrosine kinase ROR1 (ROR1) | Target Info | . | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05139017) A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003). U.S.National Institutes of Health. | |||
| REF 2 | ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365-3377. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.